

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (withdrawn)
2. (canceled)
- 3.-6. (withdrawn)
7. (canceled)
8. (canceled)
- 9.-11. (withdrawn)
12. (canceled)
13. (currently amended) A method for stimulating an immune response in a patient, comprising administering to the patient a composition of claim 1220.
R1
14. (currently amended) A method for the treatment of a lung cancer in a patient, comprising administering to the patient a composition of claim 1220.
- 15.-19. (withdrawn)
20. (new) An immunogenic composition comprising an adjuvant, wherein said adjuvant induces a predominantly Th1-type response, and a polypeptide selected from the group consisting of:
 - (i) a polypeptide comprising the amino acid sequence provided in SEQ ID NO:176, or a portion thereof;
 - (ii) a polypeptide comprising an amino acid sequence having at least 90% identity to the sequence provided in SEQ ID NO:176, or a portion thereof;
wherein said polypeptide contains an amino acid sequence that is capable of stimulating T cells that are specific for an amino acid sequence present in the polypeptide set forth in SEQ ID NO:176.
21. (new) The immunogenic composition according to claim 20, wherein the adjuvant comprises an adjuvant selected from the group consisting of a monophosphoryl lipid A, an aluminum salt, QS21, Montanide ISA 720, SAF, ISCOMS, MF-59, SBAS-2, SBAS-4, Detox, RC-529, and an aminoalkyl glucosaminide 4-phosphate.
22. (new) The immunogenic composition according to claim 20, wherein said polypeptide comprises amino acid positions 37-55 of the amino acid sequence provided in SEQ ID NO:176.
23. (new) The immunogenic composition according to claim 20, wherein said polypeptide comprises amino acid positions 41-51 of the amino acid sequence provided in SEQ ID NO:176.